Product
BPX-701
1 clinical trial
3 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Uveal melanomaClinical trial
A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal MelanomaStatus: Terminated, Estimated PCD: 2019-07-19